{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:08:50Z","timestamp":1785434930719,"version":"3.56.0"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/055mhsv54","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background and Methods: Sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD) is a severe complication of allogeneic stem cell transplant (allo-SCT). Given the increased use of allo-SCT and variability of SOS\/VOD incidence in published reports, cases of allo-SCT from two major transplant centers in Ontario, Canada (2019\u20132021), were reviewed to identify risk factors prognostic for SOS\/VOD onset and to assess outcomes. Results: This study included 536 allo-SCT cases, with a mean age of 53.4 years [min\u2013max: 17\u201376], including 322 male recipients and 214 female recipients. There were 17 SOS\/VOD cases diagnosed during the first 100 days, representing 3% of allo-SCT cases, with a median age of 48 years [18\u201372] and equally distributed between genders. All cases were classical SOS\/VOD, with onset prior to day 21 [1\u201320]. These cases were graded as one mild, six moderate, six severe, and four very severe cases. The mild case of SOS\/VOD recovered after treatment with diuretics. In respect to the 16 cases graded as \u2265moderate SOS\/VOD, the average inpatient stay was 56 days [24\u2013178], and eight patients were in the ICU for an average of 6 days [0\u201342], with a median of zero days. Five of the sixteen \u2265moderate SOS\/VOD patients died within 100 days [9\u201359]\u2014four from SOS\/VOD. After day +100, five remained alive, and six died between days 125 and 419. Treatments for \u2265moderate SOS\/VOD included diuretics [n = 15], steroids [n = 3], and defibrotide [n = 9]. The nine patients treated with defibrotide were graded as moderate [n = 2], severe [n = 4], and very severe [n = 3]. Three of the nine patients treated with defibrotide died before day 100, and the other six survived beyond day 100. None of the six surviving patients died from SOS\/VOD. Univariable regression analysis identified a higher baseline absolute neutrophil count (ANC) of 4.2 \u00d7 109\/L compared to 2.6 \u00d7 109\/L [p = 0.035] and lower baseline platelet count of 104 \u00d7 109\/L compared to 140 \u00d7 109\/L [p = 0.034] in SOS\/VOD and non-SOS\/VOD cases, respectively, as independent risks for \u2265moderate SOS\/VOD. Treatment with inotuzumab ozogamicin was also identified as a risk factor for \u2265moderate SOS\/VOD (p = 0.016). The absence of late-onset SOS\/VOD in the cohort of 536 patients prompted a retrospective analysis of the data to identify potentially missed cases. Seven cases were identified as meeting the diagnostic criteria for SOS\/VOD: four classical and three late-onset. One case would have been graded as severe, and the remaining six would have been graded as very severe. Six patients were reported to have died between days 11 and 107, with four deaths before day 100. The clinical diagnoses of patients meeting diagnostic criteria for SOS\/VOD included infection (n = 3), graft-versus-host disease (GVHD) (n = 3), and pulmonary hemorrhage (n = 1). The inclusion of potentially missed cases in the analysis again suggested a lower baseline platelet count (p = 0.002) and prior treatment with inotuzumab ozogamicin (p = 0.003) as potential risk factors for SOS\/VOD. The baseline ANC was lower in this combined cohort but did not reach statistical significance (p = 0.089) as it did in the confirmed SOS\/VOD cohort (p = 0.035). Additional clinical features that were identified as statistically significant for the onset of SOS\/VOD (potential and confirmed cases) included a lower Karnofsky Performance Status (p = 0.01), the presence of pulmonary hypertension (p = 0.012), lower baseline hemoglobin (p = 0.017), and higher baseline serum ferritin (p = 0.01). Conclusions: The incidence of classical SOS\/VOD in this cohort was consistent with recent published reports and carried a high fatality rate. A higher ANC, lower platelet count at the start of the preparative regimen, and prior treatment with inotuzumab ozogamicin were identified as potential risk factors for diagnosed SOS\/VOD. Hospital and intensive care unit stays were longer in SOS\/VOD patients. There were no cases of late-onset VOD diagnosed within the first 100 days of allo-SCT transplant, which is inconsistent with recently reported incidence rates. Potentially missed cases of SOS\/VOD were identified, suggesting that this disease may be under-diagnosed and underscoring the need for ongoing education and resources to allow for early intervention.<\/jats:p>","DOI":"10.3390\/curroncol33050261","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:03:47Z","timestamp":1777536227000},"page":"261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases\u2014A Multicenter Canadian Study"],"prefix":"10.3390","volume":"33","author":[{"given":"Emily","family":"Trus","sequence":"first","affiliation":[{"name":"College of Engineering, University of Guelph, Guelph, ON N1G 2W1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ruzic","sequence":"additional","affiliation":[{"name":"Department of Graduate Studies, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Vasudevan Nampoothiri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Transplant and Cellular Therapy Program, Ottawa, ON K1H 8L6, Canada"},{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-0882","authenticated-orcid":false,"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita","family":"Dhir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Transplant and Cellular Therapy Program, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Poskus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Transplant and Cellular Therapy Program, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bordeleau","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-1602","authenticated-orcid":false,"given":"Michael","family":"Trus","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13696998.2017.1336623","article-title":"Burden of illness associated with sinusoidal obstruction syndrome\/veno-occlusive disease in patients with hematopoietic stem cell transplantation","volume":"20","author":"Cao","year":"2017","journal-title":"J. Med. Econ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41409-023-02077-2","article-title":"Current incidence, severity, and management of veno-occlusive disease\/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: An EBMT Transplant Complications Working Party study","volume":"58","author":"Ruutu","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/ajh.27715","article-title":"Classical and Late-Onset SOS\/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis","volume":"100","author":"Masuda","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41409-019-0474-8","article-title":"Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS)","volume":"54","author":"Richardson","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: Current situation and perspectives\u2014A position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: A multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results from the International Compassionate-Use Program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Richardson","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/curroncol30110723","article-title":"Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study","volume":"30","author":"Seftel","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy\u2014A Report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","article-title":"Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: Long-term follow-up of a randomized study","volume":"20","author":"Ruutu","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","article-title":"A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"42","author":"Corbacioglu","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41409-025-02598-y","article-title":"Management of liver sinusoidal obstruction syndrome\/veno-occlusive disease in adults: A 2025 perspective from an international expert group","volume":"60","author":"Larue","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"914.e1","DOI":"10.1016\/j.jtct.2024.06.003","article-title":"Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH)","volume":"30","author":"Chinea","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1160\/TH09-10-0700","article-title":"Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy","volume":"103","author":"Stoffel","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: A new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/MEG.0000000000001802","article-title":"Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: Incidence and associated risk factors, a meta-analysis","volume":"33","author":"Xia","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bonifazi, F., Barbato, F., Ravaioli, F., Sessa, M., Defrancesco, I., Arpinati, M., Cavo, M., and Colecchia, A. (2020). Diagnosis and Treatment of VOD\/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00489"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41423-020-00581-9","article-title":"Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Tecchio","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Andrade, B., Cunill, V., Andreu, V., Bento, L., Segura-Guerrero, M., Mo\u00f1ino, A., Iglesias, J., Juli\u00e0, M.R., Dur\u00e1n, M.A., and Ballester, M.C. (2024). Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS in vitro and correlates with inflammatory parameters and clinical severity. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1353106"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3324\/haematol.2019.238790","article-title":"Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel","volume":"106","author":"Jiang","year":"2021","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41409-020-01135-3","article-title":"Underdiagnosed veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: An analysis from the EBMT Acute Leukemia Working Party","volume":"56","author":"Bazarbachi","year":"2021","journal-title":"Bone Marrow Transplant."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:16:48Z","timestamp":1777695408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050261"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050261","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}